9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Estimated reading time: < 1 min

Condition: Malignant Mesothelioma

Estimated Enrollment: 72

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: Has Results

Outcome Measures: Progression-free Survival,  Overall Survival,  Response Rate, Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)

Interventions: pemetrexed disodium, clinical observation

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: July 2017

Completion Date:

Last  Posted Date: March 5, 2019

Location: Mayo Clinic Scottsdale, Scottsdale, Arizona, United States

Website Link: https://ClinicalTrials.gov/show/NCT01085630

Was this article helpful?
Dislike 0